Benzinga | Sep 21, 2020 08:12AM EDT

Biocept Announces Highmark Has Made A Positive Coverage Determination On Target Selector Liquid Biopsy

SAN DIEGO, Sept.21, 2020 /PRNewswire/ --Biocept, Inc. (NASDAQ:BIOC),a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve the outcomes of patients with cancer, announces that Highmark, America's fourth largest Blue Cross Blue Shield affiliate, has made a positive coverage determination that Biocept's Target Selector liquid biopsy assay has been accepted for medical coverage for use in the diagnosis and treatment of patients with non-small cell lung cancer (NSCLC). The coverage determination follows two years of evaluation performed by the Allegheny Health Network Cancer Instituteof Biocept's liquid biopsy assay to more rapidly assess the molecular status of patients with NSCLC, enabling oncologists to select the most appropriate therapy while also reducing the overall cost of care.